Contributions
Abstract: P984
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - MS Variants
Objective: To investigate the influence of pregnancy on NMOSD (neuromyelitis optica spectrum disorder) patients positive for AQP4-Ab (antibody against aquaporin-4), MOG-Ab (antibody against myelin oligodendrocyte glycoprotein) or double negative and the relevance of preventive treatments before or during pregnancy to prevent attacks during pregnancy and post-partum.
Methods: AQP4-Ab positive, MOG-Ab positive and double negative NMOSD patients (2015 revised diagnostic criteria) with a history of > 1 informative pregnancy were enrolled from 7 referral hospitals in 3 countries. We recorded the number of attacks before pregnancy, during each trimester of pregnancy and during 12 months after delivery. The mean annualized relapse rate (ARR) was calculated for each period. We compared pregnancies on medication (for at least 3 months before conception and/or at least 7 months during the pregnancy) to pregnancies without any medication before or during pregnancy (off medication).
Results: There were 89 informative pregnancies in 58 patients (46 AQP4-Ab, 30 MOG-Ab and 13 double negative). The ARR during pregnancy decreased from that before pregnancy, and increased during the first trimester after delivery (p< 0.01 and p< 0.01, respectively) in the 3 groups with a trend toward AQP4-Ab positive pregnancies having a higher mean ARR during the pregnancy and the post-partum. Fewer attacks occurred in pregnancies on medication than in pregnancies off medication (p=0.03). There were significantly more attacks in AQP4-Ab positive patients off medication than those on medication (p=0.03), and a trend toward off medication patients having more attacks in MOG-Ab and double negative groups.
Conclusion: we showed a relevance of preventive treatment before and during pregnancy to prevent attacks during pregnancy and post-partum. Azathioprine could be envisaged, especially in AQP4-Ab NMOSD patients. Prospective studies are needed to confirm our findings.
Disclosure: nothing to disclose
Abstract: P984
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - MS Variants
Objective: To investigate the influence of pregnancy on NMOSD (neuromyelitis optica spectrum disorder) patients positive for AQP4-Ab (antibody against aquaporin-4), MOG-Ab (antibody against myelin oligodendrocyte glycoprotein) or double negative and the relevance of preventive treatments before or during pregnancy to prevent attacks during pregnancy and post-partum.
Methods: AQP4-Ab positive, MOG-Ab positive and double negative NMOSD patients (2015 revised diagnostic criteria) with a history of > 1 informative pregnancy were enrolled from 7 referral hospitals in 3 countries. We recorded the number of attacks before pregnancy, during each trimester of pregnancy and during 12 months after delivery. The mean annualized relapse rate (ARR) was calculated for each period. We compared pregnancies on medication (for at least 3 months before conception and/or at least 7 months during the pregnancy) to pregnancies without any medication before or during pregnancy (off medication).
Results: There were 89 informative pregnancies in 58 patients (46 AQP4-Ab, 30 MOG-Ab and 13 double negative). The ARR during pregnancy decreased from that before pregnancy, and increased during the first trimester after delivery (p< 0.01 and p< 0.01, respectively) in the 3 groups with a trend toward AQP4-Ab positive pregnancies having a higher mean ARR during the pregnancy and the post-partum. Fewer attacks occurred in pregnancies on medication than in pregnancies off medication (p=0.03). There were significantly more attacks in AQP4-Ab positive patients off medication than those on medication (p=0.03), and a trend toward off medication patients having more attacks in MOG-Ab and double negative groups.
Conclusion: we showed a relevance of preventive treatment before and during pregnancy to prevent attacks during pregnancy and post-partum. Azathioprine could be envisaged, especially in AQP4-Ab NMOSD patients. Prospective studies are needed to confirm our findings.
Disclosure: nothing to disclose